These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6891929)

  • 21. A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer.
    Milsted R; Habeshaw T; Kaye S; Sangster G; Macbeth F; Campbell-Ferguson J; Smith D; Calman K
    Cancer Chemother Pharmacol; 1985; 14(3):272-3. PubMed ID: 3888433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
    Ingle JN; Mailliard JA; Schaid DJ; Krook JE; Gesme DH; Windschitl HE; Pfeifle DM; Etzell PS; Gerstner JG; Long HJ
    Cancer; 1991 Jul; 68(1):34-9. PubMed ID: 2049750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
    Boccardo F; Rubagotti A; Amoroso D; Sismondi P; Genta F; Nenci I; Piffanelli A; Farris A; Castagnetta L; Traina A
    Eur J Cancer; 1992; 28(2-3):673-80. PubMed ID: 1591091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen.
    Mouridsen HT; Rose C; Engelsmann E; Sylvester R; Rotmensz N
    J Steroid Biochem; 1985 Dec; 23(6B):1141-6. PubMed ID: 3912619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer.
    Krook JE; Ingle JN; Green SJ; Bowman WD; Everson LK; Windschitl HE; Marschke RF; Laurie JA; Cullinan SA; Pfeifle DM
    Cancer Treat Rep; 1985 Apr; 69(4):355-61. PubMed ID: 3888386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine therapy of advanced breast cancer.
    Rose C; Mouridsen HT
    Acta Oncol; 1988; 27(6A):721-8. PubMed ID: 3064777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
    Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG
    Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
    Nomura Y; Shirouzu M; Takayama T
    Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Principles and indications of endocrine treatment of advanced breast cancer.
    Mouridsen HT; Palshof T
    Recent Results Cancer Res; 1980; 71():112-7. PubMed ID: 7367722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
    Glick JH; Creech RH; Torri S; Holroyde C; Brodovsky H; Catalano RB; Varano M
    Breast Cancer Res Treat; 1981; 1(1):59-68. PubMed ID: 6756508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
    Morgan LR; Schein PS; Woolley PV; Hoth D; Macdonald J; Lippman M; Posey LE; Beazley RW
    Cancer Treat Rep; 1976 Oct; 60(10):1437-43. PubMed ID: 191185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic overview of chemotherapy effects in breast cancer.
    Bergh J; Jönsson PE; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
    Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of endocrine therapy do not predict response to chemotherapy in advanced breast cancer.
    Steiner R; Stewart JF; Rubens RD
    Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1559-63. PubMed ID: 6685641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.